Theralink (THER) 10-Q 14 Sep 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Sep. 14, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	OncBioMune Pharmaceuticals, Inc
Entity Central Index Key	1,362,703
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		139,877,395
Trading Symbol	OBMP
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,017

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash	$ 111,895
Accounts receivable, net of allowance for doubtful accounts of $45,250	94,093
Inventories	104,616
Subscription receivable		11,190
Prepaid expenses and other current assets	75,560	30,119
Total Current Assets	386,164	41,309
OTHER ASSETS:
Property and equipment, net	8,333	9,604
Intangible assets	4,745,189
Security deposit	6,400	6,400
Total Assets	5,146,086	57,313
CURRENT LIABILITIES:
Convertible debt, net	313,194	54,688
Line of credit	99,208	99,741
Notes payable	139,125
Bank overdraft		812
Accounts payable	824,624	213,616
Accounts payable - related parties	3,599
Accrued liabilities	232,019	108,034
Derivative liabilities	1,398,465	402,055
Due to related parties	48,470	5,000
Total Current Liabilities	3,058,704	883,946
Commitments and contingencies (Note 9)
STOCKHOLDERS' EQUITY (DEFICIT):
Common stock: $.0001 par value, 500,000,000 shares authorized; 136,284,752 and 60,807,846 issued and outstanding at June 30, 2017 and December 31, 2016, respectively	13,628	6,081
Additional paid-in capital	8,262,321	2,310,037
Accumulated deficit	(6,171,340)	(3,142,851)
Accumulated other comprehensive loss	(18,116)
Total Stockholders' Equity (Deficit)	2,087,382	(826,633)
Total Liabilities and Stockholders' Equity (Deficit)	5,146,086	57,313
Series A Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT):
Preferred stock, value	$ 100	100
Series B Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT):
Preferred stock, value

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Accounts receivable, allowance for doubtful accounts	$ 45,250
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000,000	20,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	136,284,752	60,807,846
Common stock, shares outstanding	136,284,752	60,807,846
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	1,000,000	1,000,000
Preferred stock, shares outstanding	1,000,000	1,000,000
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	7,892,000	7,892,000
Preferred stock, shares issued	7,892,000	0
Preferred stock, shares outstanding	7,892,000	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
REVENUES	$ 145,723		$ 160,114
COST OF REVENUES	92,328		102,916
GROSS PROFIT	53,395		57,198
OPERATING EXPENSES:
Professional fees	535,462	184,096	949,851	311,099
Compensation expense	269,345	156,331	538,866	369,618
Consulting fees - related party	972		21,947
Research and development expense	36,318	50,449	68,232	80,535
Bad debt expense	42,246		42,246
General and administrative expenses - related party	364		8,206
General and administrative expenses	90,176	37,748	172,079	111,373
Total Operating Expenses	974,883	428,624	1,801,427	872,625
LOSS FROM OPERATIONS	(921,488)	(428,624)	(1,744,229)	(872,625)
OTHER INCOME (EXPENSE):
Interest expense	(183,481)	(6,938)	(323,361)	(7,277)
Derivative income (expense)	850,704	(144,506)	(963,529)	(144,506)
Debt settlement income, net of settlement expense	9,060		9,060
Loss on foreign currency transactions	(636)		(6,430)
Total Other Income (Expense)	675,647	(151,444)	(1,284,260)	(151,783)
NET LOSS	(245,841)	(580,068)	(3,028,489)	(1,024,408)
COMPREHENSIVE LOSS:
Net loss	(245,841)	(580,068)	(3,028,489)	(1,024,408)
Other comprehensive loss:
Unrealized foreign currency translation loss	(14,244)		(18,116)
Comprehensive loss	$ (260,085)	$ (580,068)	$ (3,046,605)	$ (1,024,408)
NET LOSS PER COMMON SHARE - Basic and Diluted:	$ 0	$ (0.01)	$ (0.03)	$ (0.02)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic and diluted	132,793,896	57,341,686	106,363,694	57,261,899

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (3,028,489)	$ (1,024,408)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	2,508	549
Stock-based compensation	153,721	35,000
Amortization of debt discount	291,668	4,167
Derivative expense	963,529	144,506
Debt settlement income	(9,060)
Bad debt expense	42,246
Change in operating assets and liabilities:
Accounts receivable	51,550
Inventories	(41,856)
Due from related parties		15,208
Prepaid expenses and other current assets	12,242	(6,701)
Accounts payable	148,710	133,939
Accounts payable - related party	(6,899)
Accrued liabilities	134,800	(53,070)
NET CASH USED IN OPERATING ACTIVITIES	(1,285,330)	(750,810)
CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of property and equipment	(715)
Acquisition of intangible assets	(50,000)
Cash received in acquisition	39,144
NET CASH USED IN INVESTING ACTIVITIES	(11,571)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from related party advances	43,439
Decrease in bank overdraft	(812)
Proceeds from line of credit		11,692
Payments to line of credit	(533)	(3,659)
Proceeds from convertible debt, net	183,240	36,000
Proceeds from notes payables	139,125
Capital contribution	482
Proceeds from sale of common stock and subscription receivable	1,037,960	46,801
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,402,901	90,834
NET INCREASE (DECREASE) IN CASH	106,000	(659,976)
Effect of exchange rate changes on cash	5,895
CASH, beginning of period		672,769
CASH, end of period	111,895	12,793
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest	4,069	339
Income taxes
Non-cash investing and financing activities:
Issuance of common stock for convertible debt	192,296
Reclassification of interest payable to convertible debt	17,836
Increase in debt discount and derivative liabilities	183,240	36,000
Issuance of common stock for services		68,000
Liabilities assumed in acquisition	433,947
Less: assets acquired in acquisition	325,702
Net liabilities assumed	108,245
Fair value of shares for acquisition	4,587,351
Increase in intangible assets	$ 4,695,596

Organization and Nature of Oper

Organization and Nature of Operations	6 Months Ended
	Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS OncBioMune Pharmaceuticals, Inc. (the “Company,” “we,” “us” or “our”) is a biotechnology company specializing in innovative cancer treatment therapies. The Company has proprietary rights to a breast and prostate patent vaccine, as well as a process for the growth of cancer tumors. The Company’s mission is to improve the overall patient condition through innovative bio immunotherapy with proven treatment protocols, to lower deaths associated with cancer and reduce the cost of cancer treatment. The Company’s technology is safe, and utilizes clinically proven research methods of treatment to provide optimal success of patient recovery. We are also developing and commercializing specialty drugs in Mexico and other Latin American countries following our March 10, 2017 acquisition of Vitel Laboratorios, S.A. de C.V. On March 10, 2017 (the “Closing Date”), the Company completed the acquisition of 100% of the issued and outstanding capital stock of Vitel Laboratorios, S.A. de C.V., a Mexican variable stock corporation (“Vitel”) from its shareholders Manuel Cosme Odabachian and Carlos Fernando Alaman Volnie (collectively, the “Vitel Stockholders”) pursuant to the terms and conditions of a Contribution Agreement to the Property of Trust F/2868 entered into among the Company and the Vitel Stockholders on the Closing Date (the “Contribution Agreement”). Vitel is a revenue-stage Mexico-based pharmaceutical company that develops and commercializes specialty drugs in MALA. The Company acquired Vitel for the purpose of commercializing the Company’s PROSCAVAX vaccine technology and cancer technologies in MALA and to utilize Vitel’s distribution network and customer and industry relationships. (See Note 3)

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation and principles of consolidation The Company’s consolidated financial statements include the financial statements of OncBioMune Pharmaceuticals, Inc. and its wholly-owned subsidiaries, OncBioMune, Inc., Vitel and Oncbiomune México, S.A. De C.V.. All significant intercompany accounts and transactions have been eliminated in consolidation. Management acknowledges its responsibility for the preparation of the accompanying unaudited condensed consolidated financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its financial position and the results of its operations for the periods presented. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”) for interim financial information and with the instructions Article 8-03 of Regulation S-X. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements These unaudited condensed consolidated financial statements should be read in conjunction with the summary of significant accounting policies and notes to the consolidated financial statements for the years ended December 31, 2016 and 2015 of the Company which were included in the Company’s annual report on Form 10-K as filed with the Securities and Exchange Commission on April 17, 2017. Going concern These consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in our accompanying consolidated financial statements, the Company had a net loss of $3,028,489 and $1,024,408 for the six months ended June 30, 2017 and 2016, respectively. The net cash used in operations were $1,285,330 and $750,810 for the six months ended June 30, 2017 and 2016, respectively. Additionally, the Company had an accumulated deficit of $6,171,340 and $3,142,851 at June 30, 2017 and at December 31, 2016, respectively, had a working capital deficit of $2,672,540 at June 30, 2017, and had minimal revenues since inception. Management believes that these matters raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the issuance date of this report. On March 10, 2017, the Company completed the acquisition of 100% of the issued and outstanding capital stock of Vitel. Management cannot provide assurance that we will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. Management believes that our capital resources are not currently adequate to continue operating and maintaining its business strategy for the fiscal year ending December 31, 2017. The Company will seek to raise capital through additional debt and/or equity financings to fund our operations in the future. Although the Company has historically raised capital from sales of equity and from the issuance of promissory notes, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail or cease operations. These consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates during the three and six months ended June 30, 2017 and 2016 include the valuation of accounts receivable, valuation of inventories, useful life of property and equipment, assumptions used in assessing impairment of long-term assets, estimates of current and deferred income taxes and deferred tax valuation allowances, the fair value of non-cash equity transactions, the valuation of derivative liabilities, and the fair value of assets acquired and liabilities assumed in the business acquisition. Fair value of financial instruments and fair value measurements FASB ASC 820 — Fair Value Measurements and Disclosures, Level 1- Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2- Inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3- Inputs are unobservable inputs that reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The carrying amounts reported in the consolidated balance sheets for cash, due from and to related parties, prepaid expenses, line of credit payable, accounts payable and accrued liabilities, approximate their fair market value based on the short-term maturity of these instruments. At June 30, 2017 At December 31, 2016 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Derivative liabilities — — $ 1,398,465 — — 402,055 A roll forward of the level 3 valuation financial instruments is as follows: Derivative Liabilities Balance at December 31, 2016 $ 402,055 Initial valuation of derivative liabilities included in debt discount 183,240 Initial valuation of derivative liabilities included in derivative expense 289,495 Reclassification of derivative liabilities to debt settlement income upon conversion (150,359 ) Change in fair value included in derivative expense 674,034 Balance at June 30, 2017 $ 1,398,465 ASC 825-10 “ Financial Instruments , Cash and cash equivalent For purposes of the consolidated statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less at the purchase date and money market accounts to be cash equivalents. At June 30, 2017 and December 31, 2016, the Company did not have any cash equivalents. The Company maintains its cash in bank and financial institution deposits that at times may exceed federally insured limits. There were no balances in excess of FDIC insured levels as of June 30, 2017 and December 31, 2016. The Company has not experienced any losses in such accounts through June 30, 2017. Additionally, the Company maintains cash at financial institutions in Mexico. At June 30, 2017 and December 31, 2016, cash balances held in Mexico banks of $82,635 and $0, respectively, are uninsured. Accounts receivable Accounts receivable are presented net of an allowance for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses. The Company reviews the accounts receivable on a periodic basis and makes general and specific allowances when there is doubt as to the collectability of individual balances. In evaluating the collectability of individual receivable balances, the Company considers many factors, including the age of the balance, a customer’s historical payment history, its current credit-worthiness and current economic trends. Accounts are written off after exhaustive efforts at collection. Inventories Inventories, consisting of finished goods related to the Company’s products are stated at the lower of cost and net realizable value utilizing the first-in first-out (FIFO) method. A reserve is established when management determines that certain inventories may not be saleable. If inventory costs exceed expected net realizable value due to obsolescence or quantities in excess of expected demand, the Company will record reserves for the difference between the cost and the net realizable value. These reserves are recorded based on estimates. Property and equipment Property are stated at cost and are depreciated using the straight-line method over their estimated useful lives, which range from three to five years. Leasehold improvements are depreciated over the shorter of the useful life or lease term including scheduled renewal terms. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. Impairment of long-lived assets In accordance with ASC Topic 360, the Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. Derivative liabilities The Company has certain financial instruments that are embedded derivatives associated with capital raises. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 810-10-05-4 and 815-40. This accounting treatment requires that the carrying amount of any embedded derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either income or expense. Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value at the conversion, repayment or exercise date and then the related fair value amount is reclassified to income or expense as part of gain or loss on extinguishment. Revenue recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the purchase price is fixed or determinable and collectability is reasonably assured. The Company records revenue when the products have been shipped to the customer. The Company reports its sales net of actual sales returns and the amount of reserves established for anticipated sales returns based on historical rates. The Company estimates and records a liability for potential returns and records this as a reduction of revenue in the same period the related revenue is recognized. The Company also offers cash discounts to certain customers as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable by the prompt pay discount amount and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized. Certain sales to distributors or retailers are made on a consignment basis. Revenue for consignment sales are not recognized until sell through to the final customer is established which may be upon receipt of payment from the Company’s customer. Stock-based compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC 505-50 – “Equity-Based Payments to Non-Employees” Basic and diluted loss per share Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. Potentially dilutive common shares consist of common stock issuable for stock warrants (using the treasury stock method). These common stock equivalents may be dilutive in the future. All potentially dilutive common shares were excluded from the computation of diluted shares outstanding as they would have an anti-dilutive impact on the Company’s net losses and consisted of the following: June 30, 2017 June 30, 2016 Stock warrants 12,098,194 2,694 Convertible debt 15,216,038 - Stock options 4,000,000 - Income taxes The Company accounts for income tax using the liability method prescribed by ASC 740, “Income Taxes”. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 “Income Taxes Research and development Research and development costs incurred in the development of the Company’s products are expensed as incurred. Foreign currency translation The reporting currency of the Company is the U.S. dollar. The functional currency of the parent company and its U.S. subsidiary is the U.S. dollar and the functional currency of the Company’s subsidiaries located in Mexico is the Mexican Peso (“Peso”). For the subsidiaries whose functional currencies are the Peso, results of operations and cash flows are translated at average exchange rates during the period, assets and liabilities are translated at the spot exchange rate at the end of the period, and equity is translated at historical exchange rates. As a result, amounts relating to assets and liabilities reported on the statements of cash flows may not necessarily agree with the changes in the corresponding balances on the balance sheets. Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in determining comprehensive loss. Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the results of operations as incurred. Additionally, transactions denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing on the transaction dates. All of the Company’s revenue transactions are transacted in the functional currency of the operating subsidiaries. The Company did not enter into any material transactions in foreign currencies. Transaction gains or losses have not had, and are not expected to have, a material effect on the results of operations of the Company. Asset and liability accounts at June 30, 2017 were translated at 18.07925 Pesos to $1.00, which was the exchange rates on the balance sheet date. Equity accounts were translated at their historical rate. The average translation rates applied to the statements of operations for the six months ended June 30, 2017 was 19.42749 Pesos to $1.00. Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rate. Related parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. Recent accounting pronouncements In August 2015, FASB issued ASU 2015-14, Deferral of the Effective Date Revenue from Contracts with Customers. Revenue from Contracts with Customers On February 25, 2016, the FASB issued ASU No. 2016-02 (“ASU 2016-02”) to amend the accounting guidance for leases. The accounting applied by a lessor is largely unchanged under ASU 2016-02. However, the standard requires lessees to recognize lease assets and lease liabilities for leases classified as operating leases on the balance sheet. Lessees will recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it will recognize lease expense for such leases generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and early adoption is permitted. The Company is currently assessing the impact of the guidance on its consolidated financial statements and notes to its consolidated financial statements. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements.

Acquisition of Vitel Laboratori

Acquisition of Vitel Laboratorios, S.A. de C.V.	6 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
Acquisition of Vitel Laboratorios, S.A. de C.V.	NOTE 3 – ACQUISITION OF VITEL LABORATORIOS, S.A. de C.V. On March 10, 2017 (the “Closing Date”), the Company completed the acquisition of 100% of the issued and outstanding capital stock of Vitel Laboratorios, S.A. de C.V., a Mexican variable stock corporation (“Vitel”) from its shareholders Manuel Cosme Odabachian and Carlos Fernando Alaman Volnie (collectively, the “Vitel Stockholders”) pursuant to the terms and conditions of a Contribution Agreement to the Property of Trust F/2868 entered into among the Company and the Vitel Stockholders on the Closing Date (the “Contribution Agreement”). Vitel is a revenue-stage Mexico-based pharmaceutical company that develops and commercializes specialty drugs in MALA. The Company acquired Vitel for the purpose of commercializing the Company’s PROSCAVAX vaccine technology and cancer technologies in MALA and to utilize Vitel’s distribution network and customer and industry relationships. Pursuant to the terms of the Contribution Agreement, the Company issued 61,158,013 shares of its common stock and 5,000,000 shares of Series B preferred stock to Banco Actinver, S.A., in its capacity as Trustee (“Banco Actinver”) of the Irrevocable Management Trust Agreement Trust No. 2868 (the “Trust Agreement”) for the benefit of the Vitel Stockholders in exchange for 100% of the issued and outstanding capital stock of Vitel (the “Vitel Shares”). The Common Stock and Series B Preferred will be held by Trustee for the benefit of the Vitel Stockholders as provided for in the Trust Agreement and 98% of the Vitel Shares are held by Banco Actinver for the benefit of the Company as provided for in the Trust Agreement and 2% of the Vitel Shares were transferred to the Company. Vitel became a wholly owned subsidiary of the Company as of the Closing Date as the Company has full control of the Vitel Shares through the Trust. In addition, the Company issued 2,892,000 shares of Series B Preferred to Jonathan F. Head, Ph. D, the Company’s Chief Executive Officer and a member of the Board of Directors of the Company (the “Board of Directors”) as provided for in the Contribution Agreement. The Series B preferred stock issued to Dr. Head and were determined to have nominal value of $289 or $.0001 per shares and was recorded as compensation expense. To induce the Vitel Stockholders to enter into the Contribution Agreement and as a condition to close the transactions set forth in that agreement, the Company, the Vitel Stockholders, Dr. Head and Andrew A. Kucharchuk, the Company’s President, Chief Financial Officer and a Director also entered into the following agreements as of the Closing Date or perform the following actions (i) a Stockholder’s Agreement among the Company, Dr. Head, Mr. Kucharchuk, Mr. Cosme and Mr. Alaman dated as of the Closing Date (the “Stockholders’ Agreement”); (ii) the Trust Agreement; (iii) the Company, Vitel and the Vitel Stockholders entered into employment agreements with Messrs. Cosme and Alaman; (iv) the Company and Dr. Head and Mr. Kucharchuk entered into amendments to the employment agreements with, and stock option awards to, Dr. Head and Mr. Kucharchuk; (v) the Company, Dr. Head, Mr. Kucharchuk and the Vitel Stockholders agreed to consent to an amendment to the Company’s Articles of Incorporation and bylaws; (vi) and to elect Mr. Cosme, Mr. Alaman, Dr. Head and Mr. Kucharchuk as directors of Vitel and such directors to elect Mr. Cosme, Mr. Alaman, Dr. Head and Mr. Kucharchuk as officers of Vitel. The Stockholders Agreement The following is a summary of Stockholders Agreement. The Vitel Stockholders and the Company established a trust pursuant to the Trust Agreement described below. Mr. Cosme and Mr. Alaman each contributed, assigned and transferred to the Company ownership of, and title over, one share of the capital stock of Vitel (the “Vitel Shares”) and Mr. Cosme and Mr. Alaman contributed, assigned and transferred to Banco Actinver (as defined in the Trust Agreement”) ownership of, and title over, the remaining 98 Vitel Shares for the benefit of the Company pursuant to the terms and conditions of the Trust Agreement. The Company contributed, assigned and transferred to Banco Actinver ownership of, and title over, 61,158,013 newly-issued shares of Common Stock and 5,000,000 newly-issued shares of Series B Preferred Stock with 100 votes per share (collectively, the “OBM Shares”), for the benefit of Mr. Cosme and Mr. Alaman pursuant to the terms and conditions of the Trust Agreement. The OBM Shares held by the Trust have not been and will not be registered under the Securities Act of 1933, as amended, (“Securities Act”) and are restricted securities under the Securities Act and the rules and regulations promulgated thereunder and are subject to the restrictions on transfer contained in Article 4 of the Shareholders’ Agreement. Corporate Rights. The corporate rights resulting from the Vitel Shares contributed to the Trust will be exercised by Banco Actinver pursuant to the written instructions it receives from the Company. For such purposes, and pursuant to the bylaws of Vitel, the Company shall have the authority to instruct Banco Actinver regarding exercising any corporate rights it may be entitled to in its capacity as the majority Vitel shareholder. Composition of the Board of Directors. Board of Directors Resolutions. Restrictions on Transfer. Permitted Transferees Permitted Transfer Right of First Refusal Right of Co-Sale (Tag Along) Drag Along Termination Effective as of March 10, 2017, Mr. Cosme, Mr. Alaman and the Company entered into the Irrevocable Management Trust Agreement Number F/2868 between Mr. Cosme, Mr. Alaman, the Company and Banco Actinver (the “Trust Agreement”) for the purpose of establishing a trust to hold the OBM Shares and 98 shares of Vitel’s capital stock which were transferred to Trustee pursuant to the Trust Agreement, in addition to other property the beneficiaries may elect to contribute to the trust. The trust structure of this acquisition transaction was established in order to provide certain income tax benefits to the seller pursuant to Mexican tax law. In connection with the acquisition, the Company issued 61,158,013 unregistered shares of its common stock valued at $4,586,851, based on the acquisition-date fair value of our common stock of $.075 per share based on recent sales of the Company’s common stock pursuant to unit subscription agreements and 5,000,000 shares of Series B preferred stock which primarily gives the holder voting rights and were determined to have nominal value of $500. The fair value of the assets acquired and liabilities assumed were based on management estimates of the fair values on March 10, 2017. Based upon the purchase price allocation, the following table summarizes the estimated fair value of the assets acquired and liabilities assumed at the date of acquisition: Cash $ 39,144 Accounts receivable 178,835 Inventories 54,952 Recoverable taxes 50,792 Other current assets 1,499 Property and equipment 480 Goodwill and other intangible assets 4,695,596 Total assets acquired at fair value 5,021,298 Accounts payable and accrued expenses 427,723 Payroll taxes 6,224 Total liabilities assumed 433,947 Total purchase consideration $ 4,587,351 The assets acquired and liabilities assumed are recorded at their estimated fair value on the acquisition date with subsequent changes recognized in earnings or loss. These estimates are inherently uncertain and are subject to refinement. Management develops estimates based on assumptions as a part of the purchase price allocation process to value the assets acquired and liabilities assumed as of the business combination date. As a result, during the purchase price measurement period, which may be up to one year from the business acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. After the purchase price measurement period, the Company will record adjustments to assets acquired or liabilities assumed in operating expenses in the period in which the adjustments were determined. The purchase price exceeded the fair value of the net assets acquired by approximately $4,695,596, which shall be recorded as goodwill or other intangible assets pending the Company analysis of the fair values. The fair value of intangible assets may be based upon the discounted cash flow method that involves inputs that are not observable in the market (Level 3). Goodwill assigned represents the amount of consideration transferred in excess of the fair value assigned to identifiable assets acquired and liabilities assumed. Any goodwill recorded is not expected to be deductible for U.S. income tax purposes. The Company shall record acquisition and transaction related expenses in the period in which they are incurred. During the six months ended June 30, 2017, acquisition and transaction related expenses primarily consisted of legal fees of approximately $104,000.

Line of Credit

Line of Credit	6 Months Ended
	Jun. 30, 2017
Line of Credit Facility [Abstract]
Line of Credit	NOTE 4 – LINE OF CREDIT In October 2014, the Company entered into a $100,000 revolving promissory note (the “Revolving Note”) with Regions Bank (the “Lender”). The unpaid principal balance of the Revolving Note is payable on demand and any unpaid principal and interest is payable due not later than October 27, 2017, is secured by deposits located at the Lender, and bears interest computed at a variable rate of interest which is equal to the Lender’s prime rate plus 1.7% (5.7% and 5.45% at June 30, 2017 and December 31, 2016, respectively). The Company will pay to Lender a late charge of 5.0% of any monthly payment not received by Lender within 10 calendar days after its due date. The Company may, at any time or from time to time, prepay the Revolving Note in whole or in part without penalty. At June 30, 2017 and December 31, 2016, the Company had $99,208 and $99,741, respectively, in borrowings outstanding under the Revolving Note with $792 and $259, respectively, available for borrowing under such note. The weighted average interest rate during the six months ended June 30, 2017 was approximately 5.57%.

Convertible Debt

Convertible Debt	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Convertible Debt	NOTE 5 – CONVERTIBLE DEBT November 2016 Financing On November 23, 2016, the Company entered into and closed on the transaction set forth in an Amended and Restated Securities Purchase Agreement (the “Securities Purchase Agreement”) it entered into with three institutional investors (the “Purchasers”) for the sale of the Company’s convertible notes and warrants. Pursuant to the terms provided for in the Securities Purchase Agreement, the Company issued upon closing to the Purchasers for an aggregate subscription amount of $350,000: (i) 14.29% Original Issue Discount 10% Senior Secured Convertible Notes (the “November 2016 Notes”); and (ii) warrants (the “Warrants”) to purchase 2,333,334 shares of the Company’s common stock at an exercise price of $0.175 (subject to adjustments under certain conditions as defined in the Warrants) (see below for reduction of warrant exercise price) which are exercisable for a period of five years from the Original Issue Date. The aggregate principal amount of the November 2016 Notes is $350,000 and the Company received $300,000 after giving effect to the original issue discount of $50,000. The November 2016 Notes bear interest at a rate equal to 10% per annum (which interest rate increased to 24% per annum upon the occurrence of an Event of Default (as defined in the November 2016 Notes)), have a maturity date of July 23, 2017 and are convertible (principal, and interest) at any time after the issuance date of the November 2016 Notes into shares of the Company’s Common Stock at a conversion price equal to $0.15 per share (subject to adjustment as provided in the Note) (see below for reduction for reduction of conversion price), provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the November 2016 Notes shall be convertible at 60% of the lowest closing price during the prior twenty trading days of the Common Stock as reported on the OTCQB or other principal trading market (the “Default Conversion Price”). The November 2016 Notes provide for two amortization payments on the six-month, seven-month and eight-month anniversary of the issue date with each amortization payment being one third of the total outstanding principal and interest. If the six-month amortization payment is made in cash then the payment is an amount equal to 120% of the applicable amortization payment and if the seven-month or the eight-month amortization payments are made in cash then the payment is an amount equal to 125% of the applicable amortization payment. The November 2016 Notes may be prepaid at any time until the 180th day following the Original Issue Date at an amount equal to (i) 115% of outstanding principal balance of the Note and accrued and unpaid interest during the period from the Original Issue Date through the three months following the Original Issue Date, and (ii) 120% of outstanding principal balance of the November 2016 Notes and accrued and unpaid interest during months four through six following the Original Issue Date. In order to prepay the November 2016 Notes, the Company shall provide 20 Trading Days prior written notice to the Holder, during which time the Holder may convert the November 2016 Notes in whole or in part at the Conversion Price. The November 2016 Notes and related Warrants include a down-round provision under which the conversion price and exercise price could be affected by future equity offerings undertaken by the Company or contain terms that are not fixed monetary amounts at inception. Subsequent to the date of these November 2016 Notes, the Company sold stock at a share price of $0.075 per shares. Accordingly, pursuant to these ratchet provisions, the conversion price on the November 2016 Notes and the exercise price of the November 2016 Warrants were lowered to $0.075 per share. Additionally, the total number of November 2016 Warrants were increased on a full ratchet basis by 3,111,111 (see Note 8). On May 23, 2017, in connection with the November 2016 Notes, the Company entered into forbearance agreements (the “Forbearance Agreements”) with the Purchases whereby the Purchasers waived any event of default, as defined in the November 2016 Notes. The Company failed to make a payment on May 23, 2017 to each of the Holders as required pursuant to the November 2016 Notes which resulted in an event of default under such Notes. As of result of the event of default, the aggregate amount owing under the November 2016 Notes as of May 23, 2017 was increased to $509,135 with such amount including a mandatory default amount of $141,299 and accrued interest of $17,836 resulting in debt settlement expense of $141,299. The Forbearance Agreement also provides for the Holders to forbear their right to demand an immediate cash payment of the principal amount due plus accrued interest as a result of the Company’s failure to satisfy its payment obligations to the Holder on May 23, 2017 so long as the Company complies with its other obligations under the November 2016 Notes and the other transaction documents. The Forbearance Agreements did not waive the default interest rate of 24%. In consideration therefore, and as currently set forth in the November 2016 Notes, the Holders shall be entitled to convert such notes from time to time at their discretion in accordance with the terms of the November 2016 Notes and the November 2016 Notes shall not be subject to repayment unless agreed to by the Holder of such Note. In connection with the Forbearance Agreement, the Company increased the principal balance of the November 2016 Notes by $159,135, reduced accrued interest payable by $17,836, and recorded debt settlement expense of $141,299. In May and June 2017, the Company issued 3,895,757 shares of its common stock upon the conversion of principal note balances of $192,296 (see Note 8). June 2017 Financing On June 2, 2017, the Company entered into a 2 nd nd nd The aggregate principal amount of the June 2017 Notes is $233,345 and the Company received $200,000 after giving effect to the original issue discount of $33,345. The June 2017 Notes bear interest at a rate equal to 10% per annum (which interest rate is increased to 24% per annum upon the occurrence of an Event of Default (as defined in the June 2017 Notes)), have a maturity date of February 2, 2018 and are convertible (principal, and interest) at any time after the issuance date of issuance into shares of the Company’s common stock at a conversion price equal to $0.15 per share (subject to adjustment as provided in the June 2017 Notes), provided, however, that if an event of default has occurred, regardless of whether such Event of Default has been cured or remains ongoing, the June 2017 Note shall be convertible at 60% of the lowest closing price during the prior twenty trading days of the common stock as reported on the OTCQB or other principal trading market (the “Default Conversion Price”). The June 2017 Notes provide for two amortization payments on the six-month, seven-month and eight-month anniversary of the issue date with each amortization payment being one third of the total outstanding principal and interest. If the six-month amortization payment is made in cash then the payment is an amount equal to 120% of the applicable amortization payment and if the seven-month or the eight-month amortization payments are made in cash then the payment is an amount equal to 125% of the applicable amortization payment. The June 2017 Notes may be prepaid at any time until the 180th day following the Original Issue Date at an amount equal to (i) 115% of outstanding principal balance of the Note and accrued and unpaid interest during the period from the Original Issue Date through the three months following the Original Issue Date, and (ii) 120% of outstanding principal balance of the June 2017 Notes and accrued and unpaid interest during months four through six following the Original Issue Date. In order to prepay the June 2017 Notes, the Company shall provide 20 Trading Days prior written notice to the Holder, during which time the Holder may convert the June 2017 Notes in whole or in part at the Conversion Price. The holders of the June 2017 Notes received June 2017 Warrants to purchase 1,555,633 shares of common stock. The initial exercise price for the June 2017 Warrants is $0.175 per share, subject to adjustment as described below, and the June 2017 Warrants are exercisable for five years after the issuance date. The November 2016 Notes and June 2017 Notes contain certain covenants, such as restrictions on the incurrence of indebtedness, creation of liens, payment of restricted payments, redemptions, payment of cash dividends and the transfer of assets. These Notes also contains certain adjustment provisions that apply in connection with any stock split, stock dividend, stock combination, recapitalization or similar transactions. The conversion price is also subject to adjustment if the Company issues or sells shares of its common stock for a consideration per share less than the conversion price then in effect, or issue options, warrants or other securities convertible or exchange for shares of its common stock at a conversion or exercise price less than the conversion price of these Notes then in effect. If either of these events should occur, the conversion price is reduced to the lowest price at which these securities were issued or are exercisable. The Company granted the Purchasers certain rights of first refusal on future offerings by the Company for as long as the Purchasers hold these Notes. In addition, subject to limited exceptions, the Purchasers will not have the right to convert any portion of these Note if the Purchaser, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of the Company’s Common Stock outstanding immediately after giving effect to its conversion. The Purchaser may increase or decrease this ownership limitation to any percentage not exceeding 9.99% upon 61 days prior written notice to the Company. The November 2016 and June 2017 Warrants are exercisable for shares of the Company’s common stock upon the payment in cash of the exercise price and they are also exercisable on a cashless basis at any time there is no effective registration statement registering the shares of common stock underlying the Warrants. The exercise price of these Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock and also upon any distributions of assets, including cash, stock or other property to the Company’s stockholders. The exercise price of these Warrants are also subject to full ratchet price adjustment if the Company sells or grants any option to purchase, sells or re-prices any common stock or common stock equivalents, as defined, at an exercise price lower than the then-current exercise price of these Warrants with the exception for certain exempted issuances and subject to certain limitations on the reduction of the exercise price as provided in the Warrants. In the event of a fundamental transaction, as described in these Warrants and generally including any reorganization, recapitalization or reclassification of the Common Stock, the sale, transfer or other disposition of all or substantially all of the Company’s properties or assets, the Company’s consolidation or merger with or into another person, the acquisition of more than 50% of the outstanding Common Stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by the outstanding Common Stock, the holders of these Warrants will be entitled to receive upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised these Warrants immediately prior to such fundamental transaction; provided that upon the occurrence of certain fundamental transactions, the holder can require the Company to purchase these Warrants for cash at a price equal to the higher of the Black Scholes Value of the unexercised portion of these Warrants or difference between the cash per share paid in the fundamental transaction and the exercise price per share. The holders of these Warrants will not have the right to exercise any portion of these Warrants if the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of these Warrants. In connection with the Company’s obligations under the November 2016 and June 2017 Notes, the Company entered into a Security Agreement, Pledge Agreement and Subsidiary Guaranty with Calvary Fund I LP, as agent, pursuant to which the Company granted a lien on all assets of the Company (the “Collateral”) excluding permitted indebtedness which includes a first lien held by Regions Bank in connection with the $100,000 revolving promissory note entered into with Regions Bank in October 2014, for the benefit of the Purchasers, to secure the Company’s obligations under the Notes. Upon an Event of Default (as defined in the Notes), the Purchasers may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease or dispose of the Collateral. Derivative liabilities pursuant to Notes and Warrants In connection with the issuance of the November 2016 and June 2017 Notes and Warrants, the Company determined that the terms of these Note and Warrants contain terms that included a down-round provision under which the conversion price and exercise price could be affected by future equity offerings undertaken by the Company or contain terms that are not fixed monetary amounts at inception. Accordingly, under the provisions of FASB ASC Topic No. 815-40, “Derivatives and Hedging – Contracts in an Entity’s Own Stock”, the embedded conversion option contained in the convertible instruments and the Warrants were accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value through earnings at each reporting date. The fair value of the embedded conversion option derivatives and Warrants were determined using the Binomial valuation model. At the end of each period, the Company revalued the embedded conversion option and warrants derivative liabilities. In connection with the issuance of June 2017 Notes and Warrants in June 2017, on the initial measurement date of the June 2017 Notes and Warrants, the fair values of the embedded conversion option and warrant derivatives of $472,735 was recorded as derivative liabilities, $289,495 was charged to current period operations as initial derivative expense, and $183,240 was recorded as a debt discount and will be amortized into interest expense over the term of the respective Note. At the end of the period, the Company revalued the embedded conversion option and warrant derivative liabilities. In connection with these revaluations, the Company recorded derivative expense of $674,034 and $144,506 for the six months ended June 30, 2017 and 2016, respectively. During the six months June 30, 2017, the fair value of the derivative liabilities was estimated using the Binomial valuation model with the following assumptions: Dividend rate 0 Term (in years) 0.08 to 5.00 years Volatility 187.6% to 199.6 % Risk-free interest rate 1.03% to 1.89 % For the six months ended June 30, 2017 and 2016, amortization of debt discounts related to the Notes amounted to $291,668 and $4,167, respectively, which has been included in interest expense on the accompanying consolidated statements of operations. At June 30, 2017 and December 31, 2016, the convertible debt consisted of the following: June 30, 2017 December 31, 2016 Principal amount $ 550,183 $ 350,000 Less: unamortized debt discount (236,989 ) (295,312 ) Convertible note payable, net $ 313,194 $ 54,688 At June 30, 2017 and December 31, 2016, the Company had $550,183 and $350,000, respectively, in borrowings outstanding under the Notes. The weighted average interest rate during the period ended June 30, 2017 was approximately 10.0%.

Loans Payable

Loans Payable	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Loans Payable	NOTE 6 – LOANS PAYABLE In June 2017, the Company entered into loan agreement with several third parties (the “Loans”). Pursuant to the loan agreements, the Company borrowed an aggregate of $139,125. The Loans bear interest at an annual rate of 33.3%, are unsecured, and are due on or before October 1, 2017.

Related-Party Transactions

Related-Party Transactions	6 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related-Party Transactions	NOTE 7 – RELATED-PARTY TRANSACTIONS Due to related parties From time to time, the Company receives advances from and repays such advances to the Company’s chief executive officer and chief financial officer for working capital purposes. Additionally, from time to time, Vitel’s General Manager of Global Operations and Vitel’s Chief Operations Officer, both of who are beneficial shareholders of the Company (together referred to as the Vitel Officers), paid expenses on behalf of the Company and the Company reimburses the Vitel Officers or these expenses. The advances are non-interest bearing and are payable on demand. For the six months ended June 30, 2017, due to related party activity consisted of the following: CEO CFO Vitel Officers Total Balance due to related parties at December 31, 2016 $ 5,000 $ - $ - $ 5,000 Working capital advances received 50,000 - 6,444 56,444 Repayments made (7,000 ) - (5,974 ) (12,974 ) Balance due to related parties at June 30, 2017 $ 48,000 $ - $ 470 $ 48,470 Accounts payable – related party At June 30, 2017, the Company owed $3,599 to a company owned by the Vitel Officers for consulting services performed Other During the six months ended June 30, 2017, the Company paid $21,947 and $8,206 to a company owned by the Vitel Officers for consulting fees and for administrative fees, respectively.

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Stockholders' Equity (Deficit)	NOTE 8 – STOCKHOLDERS’ EQUITY (DEFICIT) Shares Authorized On August 12, 2015, the Company filed amended and restated Articles of Incorporation with the Nevada Secretary of State to authorize 520,000,000 shares of capital stock, of which 500,000,000 shares are common stock, with a par value of $0.0001 per share (“Common Stock”), and 20,000,000 shares are preferred stock, with a par value of $0.0001 per share (“Preferred Stock”). Series A Preferred Stock On August 20, 2015, the Company filed the Certificate of Designation with the Nevada Secretary of State, designating 1,000,000 shares of the authorized 20,000,000 Preferred Stock as Series A Preferred Stock. Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action. On September 2, 2015, in connection with the Exchange, the Company issued 1,000,000 shares of the Company’s Series A Preferred Stock, representing 100% of the outstanding Series A Preferred. Of these shares, 500,000 were issued to our Chief Executive Officer and 500,000 shares were issued to a former member of our Board of Directors. As of June 30, 2017, there are 1,000,000 shares of Series A Preferred Stock issued and outstanding. Series B Preferred Stock On March 7, 2017, the Company filed a certificate of designation, preferences and rights of Series B preferred stock (the “Certificate of Designation”) with the Secretary of State of the State of Nevada to designate 7,892,000 shares of its previously authorized preferred stock as Series B preferred stock, par value $0.0001 per share and a stated value of $0.0001 per share. The Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series B preferred stock are entitled to dividends or distributions share for share with the holders of the Common Stock, if, as and when declared from time to time by the Board of Directors. The holders of shares of Series B preferred stock have the following voting rights: ● Each share of Series B preferred stock entitles the holder to 100 votes on all matters submitted to a vote of the Company’s stockholders. ● Except as otherwise provided in the Certificate of Designation, the holders of Series B preferred stock, the holders of Company common stock and the holders of shares of any other Company capital stock having general voting rights and shall vote together as one class on all matters submitted to a vote of the Company’s stockholders; and ● Commencing at any time after the date of issuance of any shares of the Series B Preferred Stock (the “Issuance Date”) and upon the earliest of the occurrence of (i) a holder of the Series B Preferred Stock owning, directly or indirectly as a beneficiary or otherwise, shares of Common Stock which are less than 5.0% of the total outstanding shares of Common Stock, (ii) the date a holder of the Series B Preferred Stock is no longer an employee of the Company or any of its subsidiaries or (iii) five years after the Issuance Date, the Company shall have the right to redeem all of the then outstanding Series B Preferred Stock held by such holder at a price equal to the Stated Value (the “Redemption Price”). The Series B Preferred Stock which is redeemed as provided for in the Certificate of Designations shall be returned to the Company (and, if not so returned, shall automatically be deemed canceled). The Redemption Price shall be mailed to such holder at the holder’s address of record, and the Series B Preferred Stock owned by such holder shall be canceled. In the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up of the Corporation, the holders of the Series B Preferred Stock shall be entitled to receive, share for share with the holders of shares of Common Stock and Series A Preferred Stock, all the assets of the Corporation of whatever kind available for distribution to stockholders, after the rights of the holders of the Series A Preferred Stock have been satisfied. In March 2017, the Company issued 2,892,000 shares of Series B Preferred to Jonathan F. Head, Ph. D, the Company’s Chief Executive Officer and a member of the Board of Directors of the Company as provided for in the Contribution Agreement. The Series B preferred stock issued to Dr. Head and were determined to have nominal value of $289 or $.0001 per shares and was recorded as compensation expense. In addition, in March 2017 the Company issued 5,000,000 shares of Series B Preferred to Banco Actinver for the benefit of the Vitel Stockholders as partial consideration in the exchange for 100% of the issued and outstanding capital stock of Vitel. (See Note 3). As of June 30, 2017, there are 7,892,000 shares of Series B Preferred issued and outstanding. Common Stock Common stock issued for services On February 27, 2017, the Company issued 150,000 shares of its unregistered common stock to an employee as a bonus for services to the Company. The shares were valued at the most recent cash price paid of $0.075 per share. In connection with these shares, the Company recorded stock-based compensation of $11,250. On April 13, 2017, the Company issued 20,000 shares of its unregistered common stock to a consultant for business development services performed. The shares were valued at the most recent cash price paid of $0.075 per share. In connection with these shares, the Company recorded stock-based compensation of $1,500. Common stock issued for acquisition On March 10, 2017, pursuant to the terms of the Contribution Agreement, the Company issued 61,158,013 shares of its unregistered common stock to Banco Actinver, S.A., in its capacity as Trustee (the “Trustee”) of the Irrevocable Management Trust Agreement Trust No. 2868 (the “Trust Agreement”) for the benefit of the Vitel Stockholders in exchange for 100% of the issued and outstanding capital stock of Vitel (See Note 3). Common stock purchase agreement On October 20, 2015, the Company entered into a common stock purchase agreement (the “Purchase Agreement”), together with a registration rights agreement (the “Registration Rights Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”). Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right to sell to, and Lincoln Park is obligated to purchase, up to $10.1 million in amounts of shares, as described below, of the Company’s common stock, subject to certain limitations, from time to time, over the 36-month period commencing on the date that a registration statement, which the Company agreed to file with the Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement, is declared effective by the SEC and a final prospectus in connection therewith is filed which occurred on December 15, 2015. The Company may direct Lincoln Park, at its sole discretion and subject to certain conditions, to purchase up to 100,000 shares of Common Stock on any business day (such purchases, “Regular Purchases”), provided that at least one business day has passed since the most recent purchase, and provided, however that Lincoln Park’s committed obligation under any single Regular Purchase shall not exceed $50,000, provided that the amount the Company may sell to Lincoln Park under a single Regular Purchase may increase under certain circumstances as described in the Purchase Agreement but in no event will the amount of a single Regular Purchase exceed $500,000. The purchase price of shares of Common Stock related to the future funding will be based on a formula tied to the prevailing market prices of such shares at the time of sales. In addition, the Company may direct Lincoln Park to purchase additional amounts as accelerated purchases if on the date of a Regular Purchase the closing sale price of the Common Stock is not below the threshold price as set forth in the Purchase Agreement. The Company’s sales of shares of Common Stock to Lincoln Park under the Purchase Agreement are limited to no more than the number of shares that would result in the beneficial ownership by Lincoln Park and its affiliates, at any single point in time, of more than 4.99% of the then outstanding shares of the Common Stock. In connection with the Purchase Agreement, the Company issued as a commitment fee to Lincoln Park 1,000,000 shares of Common Stock. Lincoln Park represented to the Company, among other things, that it was an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”)), and the Company sold the securities in reliance upon an exemption from registration contained in Section 4(a) (2) under the Securities Act. The securities sold may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Purchase Agreement and the Registration Rights Agreement contain customary representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations of the parties. The Company has the right to terminate the Purchase Agreement at any time, at no cost or penalty. Actual sales of shares of Common Stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the Common Stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. Lincoln Park has no right to require any sales by the Company, but is obligated to make purchases from the Company as it directs in accordance with the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of our shares. The net proceeds under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of its stock to Lincoln Park. The Company expects that any proceeds received by the Company from such sales to Lincoln Park under the Purchase Agreement will be used for general corporate purposes and working capital requirements. During the six months ended June 30, 2017, pursuant to the Purchase Agreement, the Company issued 2,000,000 shares of its common stock to Lincoln Park for net cash proceeds of $407,787. Common stock issued for debt conversion In June 2017, the Company issued 3,895,757 shares of its common stock upon conversion of note principal of $192,296 (see Note 5). Common stock and warrants issued for cash During the six months ended June 30, 2017, pursuant to unit subscription agreements, the Company issued 8,253,136 shares of its unregistered common stock and 4,126,579 five-year warrants to purchase common shares for an exercise price of $0.30 per common share to investors for cash proceeds of $618,983 or $0.075 per share. Warrants On June 2, 2017, in connection with the 2 nd Warrant activities for the six months ended June 30, 2017 are summarized as follows: Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Balance Outstanding December 31, 2016 3,304,872 $ 0.27 Issued on a full ratcheted basis 3,111,111 0.075 Issued in connection with financings 5,682,211 0.27 Balance Outstanding June 30, 2017 12,098,194 $ 0.20 4.53 $ 54,444 Exercisable, June 30, 2017 12,098,194 $ 0.20 4.53 $ 54,444 Stock options On March 10, 2017, the non-management members of the Board of Directors determined that it was in the best interests of the Company to reward the Company’s chief executive officer and chief financial officer of the Company by amending their employment agreements and awarding them stock options in order to provide incentives to retain and motivate them in their roles with the Company. The stock option award included options for each of them to purchase 2,000,000 shares (the “Stock Options”) of Common Stock at an exercise price of $0.25 per share. One-third of the Stock Options vest on March 10, 2017, March 10, 2018, and March 10, 2019, respectively, and are exercisable at any time after vesting until 10 years after the grant date. The Stock Options vest so long as the optionee remains an employee of the Company or a subsidiary of the Company on the vesting dates (except as otherwise provided for in the employment agreement between the Company and the optionee). The fair value of this option grant was estimated on the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: dividend yield of 0%; expected volatility of 203.4%; risk-free interest rate of 1.93%; and, an estimated holding period of 6 years. In connection with these options, the Company valued these options at a fair value of $293,598 and will record stock-based compensation expense over the vesting period. During the six months ended June 30, 2017, the Company recorded stock-based compensation expense of $140,682 related to these options. At June 30, 2017, there were 4,000,000 options outstanding and 1,333,334 options vested and exercisable. As of June 30, 2017, there was $189,615 of unvested stock-based compensation expense to be recognized through December 2026. The aggregate intrinsic value at June 30, 2017 was approximately $0 and was calculated based on the difference between the quoted share price on June 30, 2017 and the exercise price of the underlying options. Stock option activities for the six months ended June 30, 2017 are summarized as follows: Number of Option Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Balance Outstanding December 31, 2016 - $ - Granted 4,000,000 0.25 Balance Outstanding June 30, 2017 4,000,000 $ 0.25 9.70 $ 0 Exercisable, June 30, 2017 1,333,334 $ 0.25 9.70 $ 0

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9 – COMMITMENTS AND CONTINGENCIES Employment agreements On February 2, 2016, the Company entered into an employment agreement with Jonathan F. Head, Ph.D. (“Dr. Head”) to serve as the Company’s Chief Executive Officer, the term of which runs for three years (from February 2, 2016 through February 1, 2019) and renews automatically for one year periods unless a written notice of termination is provided not less than 120 days prior to the automatic renewal date. The employment agreement with Dr. Head provides that Dr. Head’s salary for calendar year 2016 shall be $275,000 and for calendar year 2017 and for each calendar year thereafter during the term of the employment agreement with Dr. Head shall be an amount determined by the Board of Directors, which in no event shall be less than the annual salary that was payable by the Company to Dr. Head for the immediately preceding calendar year. On February 2, 2016, the Company entered into an employment agreement with Andrew Kucharchuk (“Mr. Kucharchuk) to serve as the Company’s President and Chief Financial Officer, the term of which runs for three years (from February 2, 2016 through February 1, 2019) and renews automatically for one year periods unless a written notice of termination is provided not less than 120 days prior to the automatic renewal date. The employment agreement with Mr. Kucharchuk provides that Mr. Kucharchuk’s salary for calendar year 2016 shall be $200,000 and for calendar year 2017 and for each calendar year thereafter during the term of the employment agreement with Mr. Kucharchuk shall be an amount determined by the Board of Directors, which in no event shall be less than the annual salary that was payable by the Company to Mr. Kucharchuk for the immediately preceding calendar year. The above executives shall be eligible for an annual target bonus payment in an amount equal to ten percent of his base salary (“Bonus”). The Bonus is determined based on the achievement of certain performance objectives of the Company as established by the Board of Directors. The Bonus may be greater or less than the target Bonus, based on the level of achievement of the applicable performance objectives. On March 10, 2017, the non-management members of the Board of Directors determined that it was in the best interests of the Company to reward the Company’s chief executive officer and chief financial officer of the Company by amending their employment agreements and awarding them stock options in order to provide incentives to retain and motivate them in their roles with the Company. The Company amended each of the February 2, 2016 employment agreements of the Company’s chief executive officer and chief financial officer to extend the term to March 9, 2020 and to provide for 100% vesting of any unvested portion of any outstanding equity, or equity-based award granted to them by the Company upon termination of their respective employment agreements without cause, as a result of a breach of the agreement by the Company or upon their respective death or disability. The stock option award included options for each of them to purchase 2,000,000 shares (the “Stock Options”) of Common Stock at an exercise price of $0.25 per share. One-third of the Stock Options vest on March 10, 2017, March 10, 2018, and March 10, 2019, respectively, and are exercisable at any time after vesting until 10 years after the grant date. The Stock Options vest so long as the optionee remains an employee of the Company or a subsidiary of the Company on the vesting dates (except as otherwise provided for in the employment agreement between the Company and the optionee). Vitel Employment agreements On March 10, 2017, Vitel entered into employment agreements with each of Messrs. Cosme and Alaman who were the sellers of Vitel (the “Vitel Employment Agreements”). Mr. Cosme was appointed as Vitel’s General Manager of Global Operations and Mr. Alaman was appointed as its Chief Operations Officer. Both of Messrs. Cosme and Alaman will be responsible for, supervising, managing, planning, directing and organizing the activities of the Vitel and will be its two most senior executive officers reporting to Vitel’s Board of Directors with all other employees of Vitel reporting directly or indirectly to them. Each of the Vitel Employment Agreements provides for a base salary of $187,500, annual bonuses and other compensation as required under Mexican Federal Labor Law and an annual bonus target of 50% of salary based on performance objectives to be established by the Company’s Board of Directors annually. In addition, Messrs. Cosme and Alaman are entitled to a $500 monthly car allowance, health insurance reimbursement of up to $5,000 per year and other benefits required under Mexican law. The Vitel Employment Agreements also contains a non-compete provision prohibiting them from engaging in business activities that compete with Vitel’s current business and allows them to continue to operate their ongoing pharmaceuticals business so long as such business does not interfere with their duties to Vitel under their respective employment agreements. In addition, if Messrs. Cosme and Alaman seek to pursue any future business opportunities that do not interfere with their obligations to Vitel, they are required to notify the Company and provide it with a notice and an opportunity to participate in such opportunity. The Vitel Employment Agreements may be terminated upon the employee’s death or disability, and with or without cause. In the event Vitel terminates either of Messrs. Cosme and Alaman’s employment upon their death or disability, for cause (as defined in the employment agreement) or if either of them should resign without cause, the person resigning is entitled to payment of their base salary through the date of termination and certain severance payments they are legally entitled to receive under Mexican Federal Labor Law. At Vitel’s option, it may terminate their employment without cause or the employee may terminate the agreement for good cause (as defined in the agreement) in which event the person terminated is entitled to (i) the equivalent amount of the corresponding severance payment set forth in the Mexican Federal Labor Law for an unjustified dismissal, or if greater (ii) the equivalent amount of up to three years’ gross salary and certain amounts mandated under Mexican labor laws, depending on the date of termination less the number of months elapsed after March 10, 2017. The severance payment shall be paid in equal monthly installments over the remaining term so long as the employee is in compliance with the non-compete provisions provided for in the employment agreement. The Company is a guarantor of Vitel’s obligations under the Vitel Employment Agreements. The Vitel Employment Agreements do not represent additional purchase consideration.

Concentrations

Concentrations	6 Months Ended
	Jun. 30, 2017
Risks and Uncertainties [Abstract]
Concentrations	NOTE 9 – CONCENTRATIONS Geographic concentrations of sales For the six months ended June 30, 2017, total sales to customers located in Mexico represent 100% total revenues. Customer concentrations For the six months ended June 30, 2017, four customers accounted for approximately 88.7% of total sales (46.7%, 16.3%, 13.3% and 12.4%, respectively). The Company did not have customers during the 2016 periods. A reduction in sales from or loss of such customers would have a material adverse effect on the Company’s consolidated results of operations and financial condition. At June 30, 2017, four customers accounted for 94.0% of the accounts receivable balance (44.6%, 17.7%, 16.1%, and 15.6%, respectively). Vendor and product concentrations Generally, the Company relies on one vendor as a single source of raw materials to produce certain components of its cancer treatment products. The Company believe that other vendors are available to supply these materials if the Company cannot obtain these materials from its single source vendor. For the six months ended June 30, 2017, the Company purchased all of its product from one supplier located in Mexico. This supplier obtains its products from one suppler located in Germany. The loss of this supplier may have a material adverse effect on the Company’s consolidated results of operations and financial condition. During the six months ended June 30, 2017, the Company purchased and sold four products.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2017
Subsequent Events [Abstract]
Subsequent Events	NOTE 10 – SUBSEQUENT EVENTS From July 1, 2017 to September 7, 2017, the Company issued 2,292,643 shares of its common stock upon conversion of note principal of $81,285. In July 2017, pursuant to a unit subscription agreement, the Company issued 1,000,000 shares of its unregistered common stock and 500,000 five-year warrants to purchase common shares for an exercise price of $0.30 per common share to investors for cash proceeds of $50,000 or $0.05 per share. On July 5, 2017, the Company issued 300,000 shares of its unregistered common stock to a consultant for business development services performed. The shares were valued at the most recent cash price paid of $0.05 per share. In connection with these shares, the Company recorded stock-based consulting fees of $15,000. On July 26, 2017 (the “Original Issue Date”) the Company entered into and closed on a 3 rd rd rd rd These Notes contain certain covenants, such as restrictions on the incurrence of indebtedness, creation of liens, payment of restricted payments, redemptions, payment of cash dividends and the transfer of assets. These Notes also contains certain adjustment provisions that apply in connection with any stock split, stock dividend, stock combination, recapitalization or similar transactions. The conversion price is also subject to adjustment if the Company issues or sells shares of its common stock for a consideration per share less than the conversion price then in effect, or issue options, warrants or other securities convertible or exchange for shares of its common stock at a conversion or exercise price less than the conversion price of these Notes then in effect. If either of these events should occur, the conversion price is reduced to the lowest price at which these securities were issued or are exercisable. The Company granted the Purchasers certain rights of first refusal on future offerings by the Company for as long as the Purchasers hold these Notes. In addition, subject to limited exceptions, the Purchasers will not have the right to convert any portion of these Note if the Purchaser, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of the Company’s Common Stock outstanding immediately after giving effect to its conversion. The Purchaser may increase or decrease this ownership limitation to any percentage not exceeding 9.99% upon 61 days prior written notice to the Company. From July 1, 2017 to September 14, 2017, the Company entered into loan agreements with several third parties. Pursuant to the loan agreements, the Company borrowed an aggregate of $344,723. The loans bear interest at an annual rate of 33.3%, are unsecured, and are due on or before January 1, 2018. These Warrants are exercisable for shares of the Company’s common stock upon the payment in cash of the exercise price and they are also exercisable on a cashless basis at any time there is no effective registration statement registering the shares of common stock underlying the Warrants. The exercise price of these Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock and also upon any distributions of assets, including cash, stock or other property to the Company’s stockholders. The exercise price of these Warrants are also subject to full ratchet price adjustment if the Company sells or grants any option to purchase, sells or re-prices any common stock or common stock equivalents, as defined, at an exercise price lower than the then-current exercise price of these Warrants with the exception for certain exempted issuances and subject to certain limitations on the reduction of the exercise price as provided in the Warrants. In the event of a fundamental transaction, as described in these Warrants and generally including any reorganization, recapitalization or reclassification of the Common Stock, the sale, transfer or other disposition of all or substantially all of the Company’s properties or assets, the Company’s consolidation or merger with or into another person, the acquisition of more than 50% of the outstanding Common Stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by the outstanding Common Stock, the holders of these Warrants will be entitled to receive upon exercise of the Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised these Warrants immediately prior to such fundamental transaction; provided that upon the occurrence of certain fundamental transactions, the holder can require the Company to purchase these Warrants for cash at a price equal to the higher of the Black Scholes Value of the unexercised portion of these Warrants or difference between the cash per share paid in the fundamental transaction and the exercise price per share. The holders of these Warrants will not have the right to exercise any portion of these Warrant if the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of shares of common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of these Warrants. In connection with the issuance of the these Notes and Warrants, the Company determined that the terms of these Note and Warrants contain terms that included a down-round provision under which the conversion price and exercise price could be affected by future equity offerings undertaken by the Company or contain terms that are not fixed monetary amounts at inception. Accordingly, under the provisions of FASB ASC Topic No. 815-40, “Derivatives and Hedging – Contracts in an Entity’s Own Stock”, the embedded conversion option contained in the convertible instruments and the Warrants were accounted for as derivative liabilities at the date of issuance and shall be adjusted to fair value through earnings at each reporting date. The fair value of the embedded conversion option derivatives and Warrants were determined using the Binomial valuation model. At the end of each period, the Company revalued the embedded conversion option and warrants derivative liabilities.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of presentation and principles of consolidation The Company’s consolidated financial statements include the financial statements of OncBioMune Pharmaceuticals, Inc. and its wholly-owned subsidiaries, OncBioMune, Inc., Vitel and Oncbiomune México, S.A. De C.V.. All significant intercompany accounts and transactions have been eliminated in consolidation. Management acknowledges its responsibility for the preparation of the accompanying unaudited condensed consolidated financial statements which reflect all adjustments, consisting of normal recurring adjustments, considered necessary in its opinion for a fair statement of its financial position and the results of its operations for the periods presented. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (the “U.S. GAAP”) for interim financial information and with the instructions Article 8-03 of Regulation S-X. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. Certain information and note disclosure normally included in financial statements prepared in accordance with U.S. GAAP has been condensed or omitted from these statements pursuant to such accounting principles and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements These unaudited condensed consolidated financial statements should be read in conjunction with the summary of significant accounting policies and notes to the consolidated financial statements for the years ended December 31, 2016 and 2015 of the Company which were included in the Company’s annual report on Form 10-K as filed with the Securities and Exchange Commission on April 17, 2017.
Going Concern	Going concern These consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in our accompanying consolidated financial statements, the Company had a net loss of $3,028,489 and $1,024,408 for the six months ended June 30, 2017 and 2016, respectively. The net cash used in operations were $1,285,330 and $750,810 for the six months ended June 30, 2017 and 2016, respectively. Additionally, the Company had an accumulated deficit of $6,171,340 and $3,142,851 at June 30, 2017 and at December 31, 2016, respectively, had a working capital deficit of $2,672,540 at June 30, 2017, and had minimal revenues since inception. Management believes that these matters raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the issuance date of this report. On March 10, 2017, the Company completed the acquisition of 100% of the issued and outstanding capital stock of Vitel. Management cannot provide assurance that we will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. Management believes that our capital resources are not currently adequate to continue operating and maintaining its business strategy for the fiscal year ending December 31, 2017. The Company will seek to raise capital through additional debt and/or equity financings to fund our operations in the future. Although the Company has historically raised capital from sales of equity and from the issuance of promissory notes, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail or cease operations. These consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Use of Estimates	Use of estimates The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates during the three and six months ended June 30, 2017 and 2016 include the valuation of accounts receivable, valuation of inventories, useful life of property and equipment, assumptions used in assessing impairment of long-term assets, estimates of current and deferred income taxes and deferred tax valuation allowances, the fair value of non-cash equity transactions, the valuation of derivative liabilities, and the fair value of assets acquired and liabilities assumed in the business acquisition.
Fair Value of Financial Instruments and Fair Value Measurements	Fair value of financial instruments and fair value measurements FASB ASC 820 — Fair Value Measurements and Disclosures, Level 1- Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2- Inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3- Inputs are unobservable inputs that reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. The carrying amounts reported in the consolidated balance sheets for cash, due from and to related parties, prepaid expenses, line of credit payable, accounts payable and accrued liabilities, approximate their fair market value based on the short-term maturity of these instruments. At June 30, 2017 At December 31, 2016 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Derivative liabilities — — $ 1,398,465 — — 402,055 A roll forward of the level 3 valuation financial instruments is as follows: Derivative Liabilities Balance at December 31, 2016 $ 402,055 Initial valuation of derivative liabilities included in debt discount 183,240 Initial valuation of derivative liabilities included in derivative expense 289,495 Reclassification of derivative liabilities to debt settlement income upon conversion (150,359 ) Change in fair value included in derivative expense 674,034 Balance at June 30, 2017 $ 1,398,465 ASC 825-10 “ Financial Instruments ,
Cash and Cash Equivalent	Cash and cash equivalent For purposes of the consolidated statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less at the purchase date and money market accounts to be cash equivalents. At June 30, 2017 and December 31, 2016, the Company did not have any cash equivalents. The Company maintains its cash in bank and financial institution deposits that at times may exceed federally insured limits. There were no balances in excess of FDIC insured levels as of June 30, 2017 and December 31, 2016. The Company has not experienced any losses in such accounts through June 30, 2017. Additionally, the Company maintains cash at financial institutions in Mexico. At June 30, 2017 and December 31, 2016, cash balances held in Mexico banks of $82,635 and $0, respectively, are uninsured.
Accounts Receivable	Accounts receivable Accounts receivable are presented net of an allowance for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses. The Company reviews the accounts receivable on a periodic basis and makes general and specific allowances when there is doubt as to the collectability of individual balances. In evaluating the collectability of individual receivable balances, the Company considers many factors, including the age of the balance, a customer’s historical payment history, its current credit-worthiness and current economic trends. Accounts are written off after exhaustive efforts at collection.
Inventories	Inventories Inventories, consisting of finished goods related to the Company’s products are stated at the lower of cost and net realizable value utilizing the first-in first-out (FIFO) method. A reserve is established when management determines that certain inventories may not be saleable. If inventory costs exceed expected net realizable value due to obsolescence or quantities in excess of expected demand, the Company will record reserves for the difference between the cost and the net realizable value. These reserves are recorded based on estimates.
Property and Equipment	Property and equipment Property are stated at cost and are depreciated using the straight-line method over their estimated useful lives, which range from three to five years. Leasehold improvements are depreciated over the shorter of the useful life or lease term including scheduled renewal terms. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.
Impairment of Long-lived Assets	Impairment of long-lived assets In accordance with ASC Topic 360, the Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.
Derivative liabilities	Derivative liabilities The Company has certain financial instruments that are embedded derivatives associated with capital raises. The Company evaluates all its financial instruments to determine if those contracts or any potential embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 810-10-05-4 and 815-40. This accounting treatment requires that the carrying amount of any embedded derivatives be recorded at fair value at issuance and marked-to-market at each balance sheet date. In the event that the fair value is recorded as a liability, as is the case with the Company, the change in the fair value during the period is recorded as either income or expense. Upon conversion, exercise or repayment, the respective derivative liability is marked to fair value at the conversion, repayment or exercise date and then the related fair value amount is reclassified to income or expense as part of gain or loss on extinguishment.
Revenue Recognition	Revenue recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the purchase price is fixed or determinable and collectability is reasonably assured. The Company records revenue when the products have been shipped to the customer. The Company reports its sales net of actual sales returns and the amount of reserves established for anticipated sales returns based on historical rates. The Company estimates and records a liability for potential returns and records this as a reduction of revenue in the same period the related revenue is recognized. The Company also offers cash discounts to certain customers as an incentive for prompt payment. The Company accounts for cash discounts by reducing accounts receivable by the prompt pay discount amount and recognizes the discount as a reduction of revenue in the same period the related revenue is recognized. Certain sales to distributors or retailers are made on a consignment basis. Revenue for consignment sales are not recognized until sell through to the final customer is established which may be upon receipt of payment from the Company’s customer.
Stock-Based Compensation	Stock-based compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC 505-50 – “Equity-Based Payments to Non-Employees”
Basic and Diluted Loss Per Share	Basic and diluted loss per share Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. Potentially dilutive common shares consist of common stock issuable for stock warrants (using the treasury stock method). These common stock equivalents may be dilutive in the future. All potentially dilutive common shares were excluded from the computation of diluted shares outstanding as they would have an anti-dilutive impact on the Company’s net losses and consisted of the following: June 30, 2017 June 30, 2016 Stock warrants 12,098,194 2,694 Convertible debt 15,216,038 - Stock options 4,000,000 -
Income Taxes	Income taxes The Company accounts for income tax using the liability method prescribed by ASC 740, “Income Taxes”. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 “Income Taxes
Research and Development	Research and development Research and development costs incurred in the development of the Company’s products are expensed as incurred.
Foreign Currency Translation	Foreign currency translation The reporting currency of the Company is the U.S. dollar. The functional currency of the parent company and its U.S. subsidiary is the U.S. dollar and the functional currency of the Company’s subsidiaries located in Mexico is the Mexican Peso (“Peso”). For the subsidiaries whose functional currencies are the Peso, results of operations and cash flows are translated at average exchange rates during the period, assets and liabilities are translated at the spot exchange rate at the end of the period, and equity is translated at historical exchange rates. As a result, amounts relating to assets and liabilities reported on the statements of cash flows may not necessarily agree with the changes in the corresponding balances on the balance sheets. Translation adjustments resulting from the process of translating the local currency financial statements into U.S. dollars are included in determining comprehensive loss. Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the results of operations as incurred. Additionally, transactions denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing on the transaction dates. All of the Company’s revenue transactions are transacted in the functional currency of the operating subsidiaries. The Company did not enter into any material transactions in foreign currencies. Transaction gains or losses have not had, and are not expected to have, a material effect on the results of operations of the Company. Asset and liability accounts at June 30, 2017 were translated at 18.07925 Pesos to $1.00, which was the exchange rates on the balance sheet date. Equity accounts were translated at their historical rate. The average translation rates applied to the statements of operations for the six months ended June 30, 2017 was 19.42749 Pesos to $1.00. Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rate.
Related parties	Related parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
Recent Accounting Pronouncements	Recent accounting pronouncements In August 2015, FASB issued ASU 2015-14, Deferral of the Effective Date Revenue from Contracts with Customers. Revenue from Contracts with Customers On February 25, 2016, the FASB issued ASU No. 2016-02 (“ASU 2016-02”) to amend the accounting guidance for leases. The accounting applied by a lessor is largely unchanged under ASU 2016-02. However, the standard requires lessees to recognize lease assets and lease liabilities for leases classified as operating leases on the balance sheet. Lessees will recognize in the statement of financial position a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. If a lessee makes this election, it will recognize lease expense for such leases generally on a straight-line basis over the lease term. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 and early adoption is permitted. The Company is currently assessing the impact of the guidance on its consolidated financial statements and notes to its consolidated financial statements. In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying consolidated financial statements.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Schedule of Fair Value Using Level 3 Valuation Derivative Liability	The carrying amounts reported in the consolidated balance sheets for cash, due from and to related parties, prepaid expenses, line of credit payable, accounts payable and accrued liabilities, approximate their fair market value based on the short-term maturity of these instruments. At June 30, 2017 At December 31, 2016 Description Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Derivative liabilities — — $ 1,398,465 — — 402,055
Schedule of Roll Forward of Level 3 Valuation Financial Instrument	A roll forward of the level 3 valuation financial instruments is as follows: Derivative Liabilities Balance at December 31, 2016 $ 402,055 Initial valuation of derivative liabilities included in debt discount 183,240 Initial valuation of derivative liabilities included in derivative expense 289,495 Reclassification of derivative liabilities to debt settlement income upon conversion (150,359 ) Change in fair value included in derivative expense 674,034 Balance at June 30, 2017 $ 1,398,465
Schedule of Anti-Dilutive Shares Outstanding	All potentially dilutive common shares were excluded from the computation of diluted shares outstanding as they would have an anti-dilutive impact on the Company’s net losses and consisted of the following: June 30, 2017 June 30, 2016 Stock warrants 12,098,194 2,694 Convertible debt 15,216,038 - Stock options 4,000,000 -

Acquisition of Vitel Laborato19

Acquisition of Vitel Laboratorios, S.A. de C.V. (Tables)	6 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
Summarizes the Estimated Fair Value of Assets Acquired and Liabilities Assumed	Based upon the purchase price allocation, the following table summarizes the estimated fair value of the assets acquired and liabilities assumed at the date of acquisition: Cash $ 39,144 Accounts receivable 178,835 Inventories 54,952 Recoverable taxes 50,792 Other current assets 1,499 Property and equipment 480 Goodwill and other intangible assets 4,695,596 Total assets acquired at fair value 5,021,298 Accounts payable and accrued expenses 427,723 Payroll taxes 6,224 Total liabilities assumed 433,947 Total purchase consideration $ 4,587,351

Convertible Debt (Tables)

Convertible Debt (Tables)	6 Months Ended
	Jun. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Liabilities at Fair Value	During the six months June 30, 2017, the fair value of the derivative liabilities was estimated using the Binomial valuation model with the following assumptions: Dividend rate 0 Term (in years) 0.08 to 5.00 years Volatility 187.6% to 199.6 % Risk-free interest rate 1.03% to 1.89 %
Schedule of Convertible Note	At June 30, 2017 and December 31, 2016, the convertible debt consisted of the following: June 30, 2017 December 31, 2016 Principal amount $ 550,183 $ 350,000 Less: unamortized debt discount (236,989 ) (295,312 ) Convertible note payable, net $ 313,194 $ 54,688

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Schedule of Related Parties Activity	For the six months ended June 30, 2017, due to related party activity consisted of the following: CEO CFO Vitel Officers Total Balance due to related parties at December 31, 2016 $ 5,000 $ - $ - $ 5,000 Working capital advances received 50,000 - 6,444 56,444 Repayments made (7,000 ) - (5,974 ) (12,974 ) Balance due to related parties at June 30, 2017 $ 48,000 $ - $ 470 $ 48,470

Stockholders' Equity (Deficit)

Stockholders' Equity (Deficit) (Tables)	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Schedule of Warrant Activities	Warrant activities for the six months ended June 30, 2017 are summarized as follows: Number of Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Balance Outstanding December 31, 2016 3,304,872 $ 0.27 Issued on a full ratcheted basis 3,111,111 0.075 Issued in connection with financings 5,682,211 0.27 Balance Outstanding June 30, 2017 12,098,194 $ 0.20 4.53 $ 54,444 Exercisable, June 30, 2017 12,098,194 $ 0.20 4.53 $ 54,444
Schedule of Stock Option Activities	Stock option activities for the six months ended June 30, 2017 are summarized as follows: Number of Option Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Balance Outstanding December 31, 2016 - $ - Granted 4,000,000 0.25 Balance Outstanding June 30, 2017 4,000,000 $ 0.25 9.70 $ 0 Exercisable, June 30, 2017 1,333,334 $ 0.25 9.70 $ 0

Organization and Nature of Op23

Organization and Nature of Operations (Details Narrative)	Jun. 30, 2017	Mar. 10, 2017
Acquisition percentage of issued and outstanding	50.00%
Vitel Laboratorios, S.A. de C.V [Member]
Acquisition percentage of issued and outstanding		100.00%

Summary of Significant Accoun24

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Mar. 10, 2017	Dec. 31, 2016	Dec. 31, 2015
Net loss	$ 245,841	$ 580,068	$ 3,028,489	$ 1,024,408
Net cash used in operations			1,285,330	750,810
Accumulated deficit	6,171,340		6,171,340			$ 3,142,851
Working capital deficit	$ 2,672,540		$ 2,672,540
Acquisition percentage of issued and outstanding	50.00%		50.00%
Cash and cash equivalents
Cash at bank	111,895	$ 12,793	$ 111,895	$ 12,793			$ 672,769
Foreign currency translation description			Asset and liability accounts at June 30, 2017 were translated at 18.07925 Pesos to $1.00, which was the exchange rates on the balance sheet date. Equity accounts were stated at their historical rate. The average translation rates applied to the statements of operations for the six months ended June 30, 2017 was 19.42749 Pesos to $1.00. Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rate.
Mexico Banks [Member]
Cash at bank	$ 82,635		$ 82,635			$ 0
Vitel [Member]
Acquisition percentage of issued and outstanding					100.00%

Summary of Significant Accoun25

Summary of Significant Accounting Policies - Schedule of Fair Value Using Level 3 Valuation Derivative Liability (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Derivative liabilities	$ 1,398,465	$ 402,055
Level 1 [Member]
Derivative liabilities
Level 2 [Member]
Derivative liabilities
Level 3 [Member]
Derivative liabilities	$ 1,398,465	$ 402,055

Summary of Significant Accoun26

Summary of Significant Accounting Policies - Schedule of Roll Forward of Level 3 Valuation Financial Instrument (Details) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Accounting Policies [Abstract]
Balance at the Beginning	$ 402,055
Initial valuation of derivative liabilities included in debt discount	183,240
Initial valuation of derivative liabilities included in derivative expense	289,495
Reclassification of derivative liabilities to debt settlement income upon conversion	(150,359)
Change in fair value included in derivative expense	674,034	$ 144,506
Balance at the End	$ 1,398,465

Summary of Significant Accoun27

Summary of Significant Accounting Policies - Schedule of Anti-Dilutive Shares Outstanding (Details) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Convertible Debt [Member]
Total antidilutive securities excluded from computation of earnings per share	15,216,038
Stock Options [Member]
Total antidilutive securities excluded from computation of earnings per share	4,000,000
Stock Warrants [Member]
Total antidilutive securities excluded from computation of earnings per share		2,694
Stock Warrants [Member]
Total antidilutive securities excluded from computation of earnings per share	12,098,194

Acquisition of Vitel Laborato28

Acquisition of Vitel Laboratorios, S.a. De C.v. (Details Narrative) - USD ($)	Mar. 10, 2017	Jun. 30, 2017
Acquisition percentage of issued and outstanding		50.00%
Business acquisition description	The Common Stock and Series B Preferred will be held by Trustee for the benefit of the Vitel Stockholders as provided for in the Trust Agreement and 98% of the Vitel Shares are held by Banco Actinver for the benefit of the Company as provided for in the Trust Agreement and 2% of the Vitel Shares were transferred to the Company. Vitel became a wholly owned subsidiary of the Company as of the Closing Date as the Company has full control of the Vitel Shares through the Trust.
Debt interest rate description	Right of Co-Sale (Tag Along). In the event that any stockholder who is a party to the Stockholders’ Agreement or group of such stockholders intends to accept an offer (either solicited or unsolicited) from any third party to acquire or otherwise transfer Company Securities (as defined in the Stockholders’ Agreement), representing at least 20% of the outstanding Company Securities, on a fully diluted basis, the selling stockholder shall give an offer notice in writing to the other stockholders of the Company who are a party to the Stockholders’ Agreement, with a copy to the Company, containing the terms and conditions of such offer received from the interested third party. Each such stockholder shall have the right to participate in such offer by selling the pro rata proportion of its Company Securities pursuant to such offer to acquire or otherwise Transfer Company Securities (as defined in the Stockholders’ Agreement).
Number of unregistered shares of common stock issued		61,158,013
Number of unregistered shares of common stock value		$ 4,586,851
Fair value of common stock per share	$ 0.25	$ .075
Total assets acquired at fair value		$ 5,021,298
Legal fees		$ 104,000
Vitel Stockholders [Member]
Acquisition percentage of issued and outstanding	100.00%
Jonathan [Member]
Number of common stock shares issued	2,892,000
Number of common stock shares issued, value	$ 289
Series B Preferred Stock [Member]
Number of common stock shares issued	5,000,000
Contribution Agreement [Member]
Number of common stock shares issued	61,158,013
Stockholders Agreement [Member]
Number of common stock shares issued		61,158,013
Debt interest rate description		Right of Co-Sale (Tag Along). In the event that any stockholder who is a party to the Stockholders’ Agreement or group of such stockholders intends to accept an offer (either solicited or unsolicited) from any third party to acquire or otherwise transfer Company Securities (as defined in the Stockholders’ Agreement), representing at least 20% of the outstanding Company Securities, on a fully diluted basis, the selling stockholder shall give an offer notice in writing to the other stockholders of the Company who are a party to the Stockholders’ Agreement, with a copy to the Company, containing the terms and conditions of such offer received from the interested third party. Each such stockholder shall have the right to participate in such offer by selling the pro rata proportion of its Company Securities pursuant to such offer to acquire or otherwise Transfer Company Securities (as defined in the Stockholders’ Agreement).
Common stock outstanding, percentage description		Drag Along. In the event a stockholder who is a party to the Stockholders’ Agreement or group of such stockholders representing at least 32% (thirty two per cent) of the outstanding Company Securities, on a fully diluted basis, intends to accept an offer from any third party to acquire or otherwise Transfer Company Securities, representing at least 50% of the outstanding Company Securities, on a fully diluted basis, and the transaction is approved by the Board of Directors as a Major Decision, then each such stockholder shall be obligated to sell its Company Securities pursuant to the offer to purchase.
Stockholders Agreement [Member] | Maximum [Member]
Diluted shares percentage		5.00%
Stockholders Agreement [Member] | Series B Preferred Stock [Member]
Number of common stock shares issued		5,000,000
Stockholder voting rights		Series B Preferred Stock with 100 votes per share
Subscription Agreements [Member] | Series B Preferred Stock [Member]
Preferred stock shares issued		5,000,000
Preferred stock nominal value		$ 500
Vitel Laboratorios, S.A. de C.V [Member]
Acquisition percentage of issued and outstanding	100.00%

Acquisition of Vitel Laborato29

Acquisition of Vitel Laboratorios, S.a. De C.v. - Summarizes the Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details)	Jun. 30, 2017USD ($)
Business Combinations [Abstract]
Cash	$ 39,144
Accounts receivable	178,835
Inventories	54,952
Recoverable taxes	50,792
Other current assets	1,499
Property and equipment	480
Goodwill and other intangible assets	4,695,596
Total assets acquired at fair value	5,021,298
Accounts payable and accrued expenses	427,723
Payroll taxes	6,224
Total liabilities assumed	433,947
Total purchase consideration	$ 4,587,351

Line of Credit (Details Narrati

Line of Credit (Details Narrative) - USD ($)	Oct. 31, 2014	Jun. 30, 2017	Dec. 31, 2016
Line of credit		$ 99,208	$ 99,741
Line of credit interest rate		5.70%	5.45%
Late charge of monthly payment percentage		5.00%
Available to borrow under the line of credit		$ 792	$ 259
Weighted average interest rate		5.57%	5.57%
Prime Rate [Member]
Line of credit interest rate		1.70%
Revolving Credit Facility [Member] | Regions Bank [Member]
Line of credit	$ 100,000
Line of credit expiration date	Oct. 27, 2017

Convertible Debt (Details Narra

Convertible Debt (Details Narrative) - USD ($)	Jun. 02, 2017	May 23, 2017	Nov. 23, 2016	Jun. 30, 2017	May 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Debt face amount			$ 350,000	$ 550,183		$ 550,183		$ 550,183		$ 350,000
Proceeds from issuance of debt			300,000
Debt original issue discount			$ 50,000
Debt bear interest			10.00%
Debt maturity date			Jul. 23, 2017
Debt conversion price			$ 0.15
Conversion price, percentage			60.00%
Convertible debt conversion description			(i) 115% of outstanding principal balance of the Note and accrued and unpaid interest during the period from the Original Issue Date through the three months following the Original Issue Date, and (ii) 120% of outstanding principal balance of the November 2016 Notes and accrued and unpaid interest during months four through six following the Original Issue Date. In order to prepay the November 2016 Notes, the Company shall provide 20 Trading Days prior written notice to the Holder, during which time the Holder may convert the November 2016 Notes in whole or in part at the Conversion Price.					In addition, subject to limited exceptions, the Purchasers will not have the right to convert any portion of these Note if the Purchaser, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of the Company’s Common Stock outstanding immediately after giving effect to its conversion. The Purchaser may increase or decrease this ownership limitation to any percentage not exceeding 9.99% upon 61 days prior written notice to the Company.
Debt settlement expense						$ (9,060)		$ (9,060)
Common stock upon the conversion of debt, shares				3,895,757	3,895,757			3,895,757
Common stock upon the conversion of debt				$ 192,296	$ 192,296			$ 192,296
Beneficially ownership percentage				50.00%		50.00%		50.00%
Acquisition percentage of common stock				50.00%		50.00%		50.00%
Revolving line of credit				$ 99,208		$ 99,208		$ 99,208		$ 99,741
Warrant derivatives								472,735
Derivative liabilities				$ 289,495		$ 289,495		289,495
Amortization of debt discounts								291,668	4,167
Fair value included in derivative expense								$ 674,034	$ 144,506
November 2016 Notes [Member]
Sale of stock price per share				$ 0.075		$ 0.075		$ 0.075
Warrant exercise price				$ 0.075		$ 0.075		$ 0.075
Number of warrants increased				3,111,111		3,111,111		3,111,111
Convertible Note [Member]
Weighted average interest rate				10.00%		10.00%		10.00%
June 2017 Warrants [Member]
Warrant exercise price	$ 0.175
Warrant to purchase common shares	1,555,633
Warrant term	5 years
Amortization of debt discounts								$ 183,240
Stock Warrants [Member]
Beneficially ownership percentage				9.99%		9.99%		9.99%
Revolving line of credit				$ 100,000		$ 100,000		$ 100,000
Six Month Amortization [Member]
Amortization debt percentage	120.00%		120.00%
Seven Or Eight Month Amortization [Member]
Amortization debt percentage	125.00%		125.00%
Maximum [Member]
Debt bear interest			24.00%
Securities Purchase Agreement [Member]
Debt face amount			$ 350,000
Debt instrument description			(i) 14.29% Original Issue Discount 10% Senior Secured Convertible Notes (the “November 2016 Notes”); and (ii) warrants (the “Warrants”) to purchase 2,333,334 shares of the Company’s common stock at an exercise price of $0.175 (subject to adjustments under certain conditions as defined in the Warrants) (see below for reduction of warrant exercise price) which are exercisable for a period of five years from the Original Issue Date.
Forbearance Agreement [Member] | November 2016 Notes [Member]
Debt bear interest		24.00%
Aggregate amount owing under the notes		$ 509,135
Debt instrument default amount		$ 141,299
Increased principal balance				159,135		159,135		159,135
Reduced accrued interest payable				$ 17,836		$ 17,836		17,836
Debt settlement expense								$ 141,299
2nd Securities Purchase Agreement [Member]
Debt face amount	$ 233,345
Debt instrument description	(i) 14.29% Original Issue Discount 10% Senior Secured Convertible Notes (the “June 2017 Notes”); and (ii) warrants (the “June 2017 Warrants”) to purchase 1,555,633 shares of the Company’s common stock, par value $0.001 per share at an exercise price of $0.175 (subject to adjustments under certain conditions as defined in the June 2017 Warrants).
Proceeds from issuance of debt	$ 200,000
Debt original issue discount	$ 33,345
Debt bear interest	10.00%
Debt maturity date	Feb. 2, 2018
Debt conversion price	$ 0.15
Conversion price, percentage	60.00%
Convertible debt conversion description	(i) 115% of outstanding principal balance of the Note and accrued and unpaid interest during the period from the Original Issue Date through the three months following the Original Issue Date, and (ii) 120% of outstanding principal balance of the June 2017 Notes and accrued and unpaid interest during months four through six following the Original Issue Date. In order to prepay the June 2017 Notes, the Company shall provide 20 Trading Days prior written notice to the Holder, during which time the Holder may convert the June 2017 Notes in whole or in part at the Conversion Price.
2nd Securities Purchase Agreements [Member] | June 2017 Warrants [Member]
Warrant exercise price	$ 0.175
Warrant to purchase common shares	1,555,633
2nd Securities Purchase Agreements [Member] | Maximum [Member]
Debt bear interest	24.00%

Convertible Debt - Schedule of

Convertible Debt - Schedule of Derivative Liabilities at Fair Value (Details)	6 Months Ended
	Jun. 30, 2017
Dividend rate	0.00%
Minimum [Member]
Term (in years)	29 days
Volatility	187.60%
Risk-free interest rate	1.03%
Maximum [Member]
Term (in years)	5 years
Volatility	199.60%
Risk-free interest rate	1.89%

Convertible Debt - Schedule o33

Convertible Debt - Schedule of Convertible Note (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Principal amount	$ 550,183	$ 350,000
Less: unamortized debt discount	(236,989)	(295,312)
Convertible note payable, net	$ 313,194	$ 54,688

Loans Payable (Details Narrativ

Loans Payable (Details Narrative) - USD ($)	Nov. 23, 2016	Jun. 30, 2017
Debt maturity date	Jul. 23, 2017
Loan Agreement [Member]
Loans payable		$ 139,125
Debt instrument, interest rate		33.30%
Debt maturity date		Oct. 1, 2017

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Consulting fees - related party	$ 972		$ 21,947
Vitel Officers [Member]
Accounts payable related party	$ 3,599		3,599
Consulting fees - related party			21,947
Administrative fees - related party			$ 8,206

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Parties Activity (Details)	6 Months Ended
	Jun. 30, 2017USD ($)
Balance due to related parties	$ 5,000
Working capital advances received	56,444
Repayments made	(12,974)
Balance due to related parties	48,470
CEO [Member]
Balance due to related parties	5,000
Working capital advances received	50,000
Repayments made	(7,000)
Balance due to related parties	48,000
CFO [Member]
Balance due to related parties
Working capital advances received
Repayments made
Balance due to related parties
Vitel Officers [Member]
Balance due to related parties
Working capital advances received	6,444
Repayments made	(5,974)
Balance due to related parties	$ 470

Stockholders' Equity (Deficit37

Stockholders' Equity (Deficit) (Details Narrative) - USD ($)	Jun. 02, 2017	Apr. 13, 2017	Mar. 10, 2017	Mar. 07, 2017	Feb. 27, 2017	Oct. 20, 2016	Sep. 02, 2015	Aug. 20, 2015	Jun. 30, 2017	May 31, 2017	Mar. 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Oct. 20, 2015	Aug. 12, 2015
Capital stock authorized																		520,000,000
Common stock, shares authorized									500,000,000			500,000,000		500,000,000		500,000,000		500,000,000
Common stock, par value									$ 0.0001			$ 0.0001		$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock, shares authorized									20,000,000			20,000,000		20,000,000		20,000,000		20,000,000
Preferred stock, par value									$ 0.0001			$ 0.0001		$ 0.0001		$ 0.0001		$ 0.0001
Common stock value per share			$ 0.25						$ .075			$ .075		$ .075
Stock-based compensation														$ 153,721	$ 35,000
Beneficial ownership percentage									50.00%			50.00%		50.00%
Common stock upon the conversion of debt, shares									3,895,757	3,895,757				3,895,757
Common stock upon the conversion of debt									$ 192,296	$ 192,296				$ 192,296
Stock option to purchase common stock			2,000,000
Stock option vesting, description			One-third of the Stock Options vest on March 10, 2017, March 10, 2018, and March 10, 2019, respectively
Stock option vesting, term			10 years
Dividend yield			0.00%
Expected volatility			203.40%
Risk-free interest rate			1.93%
Estimated holding period			6 years
Fair value of stock based compensation			$ 293,598									$ 269,345	$ 156,331	$ 538,866	$ 369,618
Stock option, outstanding									4,000,000			4,000,000		4,000,000
Stock option vested and exercisable									1,333,334			1,333,334		1,333,334
Unvested stock based compensation expenses									$ 189,615			$ 189,615		$ 189,615
Aggregate intrinsic value									$ 0			$ 0		0
Options [Member]
Stock-based compensation														$ 140,682
Contribution Agreement [Member]
Number of shares issued during period			61,158,013
Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]
Number of common stock issued value						$ 10,100,000
Maximum purchase of shares of common stock on business day						100,000
Minimum obligation commitment amount																	$ 50,000
Minimum purchase obligation amount						$ 500,000
Number of shares issued as commitment fee						1,000,000
Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member] | Maximum [Member]
Beneficial ownership percentage									4.99%			4.99%		4.99%
Unit Subscription Agreements [Member]
Number of shares issued during period														8,253,136
Common stock value per share									$ 0.075			$ 0.075		$ 0.075
Number of common stock issued value														$ 618,983
Warrant to purchase common shares									4,126,579			4,126,579		4,126,579
Warrant term														5 years
Warrants exercise price per share									$ 0.30			$ 0.30		$ 0.30
Jonathan [Member]
Number of shares issued during period			2,892,000
Number of common stock issued value			$ 289
Banco Actinver [Member] | Contribution Agreement [Member]
Common stock outstanding, percentage			100.00%
Number of shares issued during period			61,158,013
Consultant [Member]
Number of shares issued during period		20,000
Common stock value per share		$ 0.075
Stock-based compensation		$ 1,500
Lincoln Park [Member] | Purchase Agreement [Member]
Number of shares issued during period														2,000,000
Number of common stock issued value														$ 407,787
Series A Preferred Stock [Member]
Preferred stock, shares authorized								20,000,000	1,000,000			1,000,000		1,000,000		1,000,000
Preferred stock, par value									$ 0.0001			$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock shares designating								1,000,000
Stockholder voting rights								Each holder of Series A Preferred Stock shall be entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent shall not be required (except to the extent they are entitled to vote with holders of Common Stock as set forth in the Certificate of Designation) for taking any corporate action.
Number of share exchange during period							1,000,000
Percentage of outstanding shares							100.00%
Preferred stock, shares issued									1,000,000			1,000,000		1,000,000		1,000,000
Preferred stock, shares outstanding									1,000,000			1,000,000		1,000,000		1,000,000
Series A Preferred Stock [Member] | CEO [Member]
Preferred stock, shares issued							500,000
Series A Preferred Stock [Member] | Board of Directors [Member]
Preferred stock, shares issued							500,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized									7,892,000			7,892,000		7,892,000		7,892,000
Preferred stock, par value				$ 0.0001					$ 0.0001			$ 0.0001		$ 0.0001		$ 0.0001
Preferred stock shares designating				7,892,000
Stockholder voting rights				Each share of Series B preferred stock entitles the holder to 100 votes on all matters submitted to a vote of the Company’s stockholders.
Preferred stock, shares issued									7,892,000			7,892,000		7,892,000		0
Preferred stock, shares outstanding									7,892,000			7,892,000		7,892,000		0
Common stock outstanding, percentage				5.00%
Series B Preferred Stock [Member] | Jonathan [Member]
Number of shares issued during period											2,892,000
Series B Preferred Stock [Member] | Dr Head [Member]
Preferred stock, par value											$ .0001
Preferred stock nominal value											$ 289
Series B Preferred Stock [Member] | Banco Actinver [Member]
Common stock outstanding, percentage											100.00%
Number of shares issued during period											5,000,000
Series B Preferred Stock [Member] | Employee [Member]
Common stock issued for services					150,000
Common stock value per share					$ 0.075
Stock-based compensation					$ 11,250
June 2017 Warrants [Member]
Warrant to purchase common shares	1,555,633
Warrant term	5 years
Warrants exercise price per share	$ 0.175
June 2017 Warrants [Member] | 2nd Securities Purchase Agreements [Member]
Common stock, par value	$ 0.001
Warrant to purchase common shares	1,555,633
Warrants exercise price per share	$ 0.175

Stockholders' Equity (Deficit38

Stockholders' Equity (Deficit) - Schedule of Warrant Activities (Details)	6 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Weighted Average Remaining Contractual Term (Years), Exercisable	9 years 8 months 12 days
Stock Warrants [Member]
Number of Warrants, Outstanding Beginning balance | shares	3,304,872
Number of Warrants, Issued on a full ratcheted basis | shares	3,111,111
Number of Warrants, Issued in connection with financings | shares	5,682,211
Number of Warrants, Outstanding Ending balance | shares	12,098,194
Number of Warrants, Exercisable | shares	12,098,194
Weighted Average Exercise Price, Outstanding Beginning balance | $ / shares	$ 0.27
Weighted Average Exercise Price, Issued on a full ratcheted basis | $ / shares	0.075
Weighted Average Exercise Price, Issued in connection with financings | $ / shares	0.27
Weighted Average Exercise Price, Outstanding Ending balance | $ / shares	0.20
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.20
Weighted Average Remaining Contractual Term (Years), Balance Outstanding	4 years 6 months 10 days
Weighted Average Remaining Contractual Term (Years), Exercisable	4 years 6 months 10 days
Aggregate Intrinsic Value, Balance Outstanding | $	$ 54,444
Aggregate Intrinsic Value, Exercisable | $	$ 54,444

Stockholders' Equity (Deficit39

Stockholders' Equity (Deficit) - Schedule of Stock Option Activities (Details)	6 Months Ended
	Jun. 30, 2017USD ($)$ / sharesshares
Equity [Abstract]
Number of Option Outstanding, Beginning Balance | shares
Number of Option, Granted | shares	4,000,000
Number of Option Outstanding, Ending Balance | shares	4,000,000
Number of Option Exercisable | shares	1,333,334
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares
Weighted Average Exercise Price Granted | $ / shares	0.25
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	0.25
Weighted Average Exercise Price Exercisable | $ / shares	$ 0.25
Weighted Average Contractual Term (Years) Balance Outstanding	9 years 8 months 12 days
Weighted Average Contractual Term (Years) Exercisable	9 years 8 months 12 days
Aggregate Intrinsic Value Balance Outstanding | $	$ 0
Aggregate Intrinsic Value Exercisable | $	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Mar. 10, 2017	Feb. 02, 2016	Jun. 30, 2017
Stock option to purchase common stock	2,000,000
Shares issued price per share	$ 0.25		$ .075
Stock option vesting, description	One-third of the Stock Options vest on March 10, 2017, March 10, 2018, and March 10, 2019, respectively
Stock option vesting, term	10 years
Vitel Employment Agreements [Member]
Base salary	$ 187,500
Annual bonus, percentage	50.00%
Car allowances	$ 500
Vitel Employment Agreements [Member] | Maximum [Member]
Health insurance reimbursement	$ 5,000
Jonathan F. Head, Ph.D [Member] | Employment Agreements [Member]
Salary payable		$ 275,000
Andrew Kucharchuk Chief Financial Officer [Member] | Employment Agreements [Member]
Salary payable		$ 200,000
Chief Executive Officer And Chief Financial Officer [Member]
Stock option term	Mar. 9, 2020
Stock option vesting, percentage	100.00%

Concentrations (Details Narrati

Concentrations (Details Narrative)	6 Months Ended
	Jun. 30, 2017
Sales Revenue, Net [Member]
Concentration risk, percentage	88.70%
Sales Revenue, Net [Member] | Customer One [Member]
Concentration risk, percentage	46.70%
Sales Revenue, Net [Member] | Customer Two [Member]
Concentration risk, percentage	16.30%
Sales Revenue, Net [Member] | Customer Three [Member]
Concentration risk, percentage	1335.00%
Sales Revenue, Net [Member] | Customer Four [Member]
Concentration risk, percentage	12.40%
Sales Revenue, Net [Member] | Mexico [Member]
Concentration risk, percentage	100.00%
Accounts Receivable [Member]
Concentration risk, percentage	94.00%
Accounts Receivable [Member] | Customer One [Member]
Concentration risk, percentage	44.60%
Accounts Receivable [Member] | Customer Two [Member]
Concentration risk, percentage	17.70%
Accounts Receivable [Member] | Customer Three [Member]
Concentration risk, percentage	16.10%
Accounts Receivable [Member] | Customer Four [Member]
Concentration risk, percentage	15.60%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Jul. 26, 2017	Jul. 05, 2017	Apr. 13, 2017	Nov. 23, 2016	Jul. 31, 2017	Jun. 30, 2017	May 31, 2017	Sep. 14, 2017	Sep. 07, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 02, 2017	Mar. 10, 2017	Dec. 31, 2016
Number of common stock shares issued upon conversion of note principal						3,895,757	3,895,757			3,895,757
Number of common stock issued upon conversion of note principal						$ 192,296	$ 192,296			$ 192,296
Common stock value per share						$ .075				$ .075			$ 0.25
Stock-based compensation										$ 153,721	$ 35,000
Senior secured convertible notes principal amount				$ 350,000		$ 550,183				$ 550,183				$ 350,000
Debt maturity date				Jul. 23, 2017
Debt conversion price				$ 0.15
Conversion price, percentage				60.00%
Convertible debt conversion description				(i) 115% of outstanding principal balance of the Note and accrued and unpaid interest during the period from the Original Issue Date through the three months following the Original Issue Date, and (ii) 120% of outstanding principal balance of the November 2016 Notes and accrued and unpaid interest during months four through six following the Original Issue Date. In order to prepay the November 2016 Notes, the Company shall provide 20 Trading Days prior written notice to the Holder, during which time the Holder may convert the November 2016 Notes in whole or in part at the Conversion Price.						In addition, subject to limited exceptions, the Purchasers will not have the right to convert any portion of these Note if the Purchaser, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of the Company’s Common Stock outstanding immediately after giving effect to its conversion. The Purchaser may increase or decrease this ownership limitation to any percentage not exceeding 9.99% upon 61 days prior written notice to the Company.
Acquisition percentage of common stock						50.00%				50.00%
Benificially ownership interest						50.00%				50.00%
Six Month Amortization [Member]
Amortization debt percentage				120.00%								120.00%
Seven Or Eight Month Amortization [Member]
Amortization debt percentage				125.00%								125.00%
Consultant [Member]
Number of common stock shares issued			20,000
Common stock value per share			$ 0.075
Stock-based compensation			$ 1,500
Unit Subscription Agreements [Member]
Number of common stock shares issued										8,253,136
Number of common stock shares issued, value										$ 618,983
Warrant to purchase common shares						4,126,579				4,126,579
Warrant term										5 years
Warrants exercise price per share						$ 0.30				$ 0.30
Common stock value per share						$ 0.075				$ 0.075
Subsequent Event [Member]
Number of common stock shares issued upon conversion of note principal									2,292,643
Number of common stock issued upon conversion of note principal									$ 81,285
Subsequent Event [Member] | Six Month Amortization [Member]
Amortization debt percentage	110.00%
Subsequent Event [Member] | Seven Or Eight Month Amortization [Member]
Amortization debt percentage	115.00%
Subsequent Event [Member] | Consultant [Member]
Number of common stock shares issued, value		$ 300,000
Common stock value per share		$ 0.05
Stock-based compensation		$ 15,000
Subsequent Event [Member] | Unit Subscription Agreements [Member]
Number of common stock shares issued					1,000,000
Warrant to purchase common shares					500,000
Warrant term					5 years
Warrants exercise price per share					$ 0.30
Proceeds from issuance of warrants					$ 50,000
Common stock value per share					$ 0.05
Subsequent Event [Member] | 3rd Securities Purchase Agreements [Member]
Warrant to purchase common shares	4,769,763
Warrants exercise price per share	$ 0.10
Aggregate subscription amount	$ 300,000
Percentage of original debt discount	10.00%
Percentage of senior secured convertible note payable	5.00%
Senior secured convertible notes principal amount	$ 333,883
Debt bears interest rate	5.00%
Increase in debt instrument, interest rate	24.00%
Debt maturity date	Mar. 25, 2018
Debt conversion price	$ 0.07
Conversion price, percentage	60.00%
Convertible debt conversion description	In addition, subject to limited exceptions, the Purchasers will not have the right to convert any portion of these Note if the Purchaser, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of the Company’s Common Stock outstanding immediately after giving effect to its conversion. The Purchaser may increase or decrease this ownership limitation to any percentage not exceeding 9.99% upon 61 days prior written notice to the Company.									i) 115% of outstanding principal balance of the Note and accrued and unpaid interest during the period from the Original Issue Date through the three months following the Original Issue Date, and (ii) 120% of outstanding principal balance of the Notes and accrued and unpaid interest during months four through seven following the Original Issue Date. In order to prepay these Notes, the Company shall provide 20 Trading Days prior written notice to the Purchaser, during which time the Purchaser may convert the Notes in whole or in part at the Conversion Price.
Acquisition percentage of common stock	50.00%
Subsequent Event [Member] | 3rd Securities Purchase Agreements [Member] | Warrant Holder [Member]
Benificially ownership interest	9.99%
Subsequent Event [Member] | Loan Agreements [Member] | Third Parties [Member]
Debt bears interest rate								33.30%
Debt maturity date								Jan. 1, 2018
Borrowed amount								$ 344,723